Firebrick Pharma (ASX:FRE) has announced the publication of new research in The Laryngoscope, which assesses the company's Nasodine Nasal Spray as a treatment for chronic rhinosinusitis (CRS).
The pharmaceutical company says CRS is a common and difficult to treat infection of the sinuses, caused by strains of Staph. aureus.
Firebrick Pharma says Nasodine has demonstrated time and concentration-dependent bacterial killing of S. aureus biofilms, with statistically significant reductions in viable bacteria in as little as 5 minutes.
It also says it's continuing to focus on Nasodine as a treatment for the common cold, but may consider its future development in CRS.
Firebrick Pharma's share price is up 7% at the time of publication.